Notably, mutations in IDH1/2 and 1p/19q co‐deletion define distinct glioma subtypes, which exhibit better outcomes than IDH‐wildtype astrocytoma, also known as glioblastoma (GBM) [4]. This evidence concerns the gene IDH1 and glioma.